Research programme: antibody therapeutics - AnaptysBio

Drug Profile

Research programme: antibody therapeutics - AnaptysBio

Alternative Names: ANA 02; ANA 04; ANA 505; ANB 004; ANB 012; TSR-075

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnaptysBio
  • Developer AnaptysBio; TESARO
  • Class Antibodies; Antifibrotics; Antineoplastics; Antipsoriatics; Bispecific antibodies; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Checkpoint kinase inhibitors; HAVCR2 protein inhibitors; Immunomodulators; Interleukin 36 receptor antagonists; Interleukin-17 inhibitors; Membrane protein inhibitors; Nerve growth factor inhibitors; Programmed cell death-1 receptor antagonists; Type-II-B activin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Pustular psoriasis
  • No development reported Autoimmune disorders; Fibrosis; Inflammation; Muscular atrophy; Solid tumours

Most Recent Events

  • 27 Feb 2018 Preclinical trials in Cancer in USA (Parenteral) before February 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Fibrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top